Evidence mapPaperPMID 37340592Full record

SynthesisClinical cardiology2023

The added value of hypertonic saline solution to furosemide monotherapy in patients with acute decompensated heart failure: A meta-analysis and trial sequential analysis.

Carlos Diaz-Arocutipa, Jack Denegri-Galvan, Lourdes Vicent, Marcos Pariona, Mamas A Mamas, Adrian V Hernandez

Open access · goldAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Clinical cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025
    Review
  7. Review
  8. Targeting Sodium in Heart Failure.Journal of personalized medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Carlos Diaz-ArocutipaVicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.ORCID http://orcid.org/0000-0002-5101-2832
Jack Denegri-GalvanDeparment of Cardiology, Hospital Nacional Daniel Alcides Carrión, Callao, Peru.
Lourdes VicentCardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.ORCID http://orcid.org/0000-0001-7914-9788
Marcos ParionaDepartment of Cardiology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Mamas A MamasKeele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK.
Adrian V HernandezVicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Centro de Investigación en Red en Enfermedades Cardiovasculares · ESDaniel Alcides Carrión National University · PEHartford Hospital · USHospital Nacional Cayetano Heredia · PEKeele University · GBUniversidad San Ignacio de Loyola · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the effects of hypertonic saline solution (HSS) plus furosemide versus furosemide alone in patients with acute decompensated heart failure (ADHF). We searched four electronic databases for randomized controlled trials (RCTs) until June 30, 2022. The quality of evidence (QoE) was assessed using the GRADE approach. All meta-analyses were performed using a random-effects model. A trial sequential analysis (TSA) was also conducted for intermediate and biomarker outcomes. Ten RCTs involving 3013 patients were included. HSS plus furosemide significantly reduced the length of hospital stay (mean difference [MD]: -3.60 days; 95% confidence interval [CI]: -4.56 to -2.64; QoE: moderate), weight (MD: -2.34 kg; 95% CI: -3.15 to -1.53; QoE: moderate), serum creatinine (MD: -0.41 mg/dL; 95% CI: -0.49 to -0.33; QoE: low), and type-B natriuretic peptide (MD: -124.26 pg/mL; 95% CI: -207.97 to -40.54; QoE: low) compared to furosemide alone. HSS plus furosemide significantly increased urine output (MD: 528.57 mL/24 h; 95% CI: 431.90 to 625.23; QoE: moderate), serum Na

Indexed as

FurosemideHeart FailureDiureticsHumansRandomized Controlled Trials as TopicSaline Solution, HypertonicSodiumDiureticsFurosemideSaline Solution, HypertonicSodiumacute heart failurefurosemidehypertonic saline solutionsystematic review

Identifiers

PMID37340592
PMCPMC10436795
OpenAlexW4381470451

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.